Dr. Sana D. Karam
Claim this profileUniversity of Colorado Hospital
Studies Squamous Cell Carcinoma
Studies Skin Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Squamous Cell Carcinoma
p16 negative
Stage IV
Stage III
2Skin Cancer
p16 negative
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Sana D. Karam is currently running
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
TTI-101 + Radiotherapy
for Pancreatic Cancer
To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal adenocarcinoma.
Recruiting1 award Phase 1 & 217 criteria
More about Sana D. Karam
Clinical Trial Related11 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sana D. Karam has experience with
- Atezolizumab
- Cetuximab
- Durvalumab
- Standard Of Care Therapy
- Stereotactic Body Radiation Therapy (SBRT)
- TTI-101
Breakdown of trials Sana D. Karam has run
Squamous Cell Carcinoma
Skin Cancer
Pancreatic Cancer
Oral Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sana D. Karam specialize in?
Sana D. Karam focuses on Squamous Cell Carcinoma and Skin Cancer. In particular, much of their work with Squamous Cell Carcinoma has involved p16 negative patients, or patients who are Stage IV.
Is Sana D. Karam currently recruiting for clinical trials?
Yes, Sana D. Karam is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Sana D. Karam has studied deeply?
Yes, Sana D. Karam has studied treatments such as Atezolizumab, Cetuximab, Durvalumab.
What is the best way to schedule an appointment with Sana D. Karam?
Apply for one of the trials that Sana D. Karam is conducting.
What is the office address of Sana D. Karam?
The office of Sana D. Karam is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.